Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.70 |
| ▸ | ADH5 | P11766 | 4/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.59 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27893085 | 0.86 | ADH5 (0.87) | CYP3A4BAZ2BADH5HTTHTR2A | |
| SCHEMBL10574724 | 0.85 | CYP3A4 (0.74) | CYP3A4BAZ2BADH5HTTHTR2A | |
| SCHEMBL62049 | 0.84 | ADH5 (0.90) | CYP3A4BAZ2BADH5HTTHTR2A | |
| SCHEMBL27374956 | 0.82 | CYP3A4 (0.60) | CYP3A4BAZ2BADH5HTTHTR2A | |
| SCHEMBL30832962 | 0.82 | MAPT (0.61) | CYP3A4BAZ2BADH5HTTHTR2A | |
| SCHEMBL1274293 | 0.82 | CYP3A4 (0.70) | CYP3A4BAZ2BADH5HTTHTR2A | |
| Hydrochloric Acid SCHEMBL6152702 | 0.82 | ADH5 (0.87) | CYP3A4BAZ2BADH5HTTHTR2A | |
| SCHEMBL611481 | 0.82 | CYP3A4 (1.00) | CYP3A4BAZ2BADH5HTTHTR2A | |
| SCHEMBL10960777 | 0.81 | CYP3A4 (0.64) | CYP3A4BAZ2BADH5HTTHTR2A | |
| SCHEMBL3118463 | 0.81 | IDO1 (0.61) | CYP3A4BAZ2BADH5HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | claimed |
| US-6812225-B2 | PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | claimed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3256218-B1 | A KDM1A INHIBITOR AND ITS USE IN THERAPY | IMAGO BIOSCIENCES INC (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220073477-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| US-4804662-A | Substituted 4-(1H-imidazol-1-yl)benzamides as antiarrhythmic agents | SCHERING A.G. (DE) | 1989-02-14 | — | — | US | disclosed |
| US-4804662-A | Substituted 4-(1H-imidazol-1-yl)benzamides as antiarrhythmic agents | SCHERING A.G. (DE) | 1989-02-14 | — | — | US | disclosed |
| US-4804662-A | Substituted 4-(1H-imidazol-1-yl)benzamides as antiarrhythmic agents | SCHERING A.G. (DE) | 1989-02-14 | — | — | US | disclosed |
| EP-0290377-A1 | Substituted 4-[1H-Imidazol-1-yl] benzamides as antiarrhythmic agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-11-09 | — | — | EP | disclosed |
| EP-0290377-A1 | Substituted 4-[1H-Imidazol-1-yl] benzamides as antiarrhythmic agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-11-09 | — | — | EP | disclosed |
| EP-0290377-A1 | Substituted 4-[1H-Imidazol-1-yl] benzamides as antiarrhythmic agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | CYP3A4 2577/4885BAZ2B 1593/4885ADH5 578/4885 |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | CYP3A4 319/4885BAZ2B 2930/4885ADH5 626/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | CYP3A4 252/4885BAZ2B 3591/4885ADH5 650/4885 |
| US-20220073477-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | CYP3A4 4183/4885BAZ2B 50/4885ADH5 1996/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | CYP3A4 4183/4885BAZ2B 50/4885ADH5 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.